trimazosin

RN given refers to parent cpd; structure

Also Known As:

2-hydroxy-2-methylpropyl 4-(4-amino-6,7,8-trimethoxy-2-quinqzolinyl)-1-piperazinecar boxylate; CP 19,106; CP-19,106; trimazosin hydrochloride; trimazosin hydrochloride, monohydrate; 4-(4-amino-6,7,8-trimethoxy-2-quinazolinyl)-1-piperazinecarboxylic acid, 2-hydroxy-2- methylpropyl ester

Networked: 35 relevant articles (7 outcomes, 3 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- 1-Ring Heterocyclic Compounds
  - Piperazines: 26
    - trimazosin: 35

Related Diseases

1.	Heart Failure 11/01/1983 - "Trimazosin in chronic congestive heart failure: improved left ventricular function at rest and during exercise." 05/01/1985 - "We evaluated chronic adjunctive alpha-1 receptor blockade with trimazosin in congestive heart failure. " 04/01/1981 - "Treatment of refractory heart failure with trimazosin." 07/31/1980 - "The ability of long-term alpha-receptor blockade and vasodilation with trimazosin (TMZ) to improve exercise capacity was studied in patients with chronic, stable heart failure of varying severity (functional exercise classes B to D). " 07/01/1979 - "This clinical investigation of the acute hemodynamic effects of trimazosin objectively demonstrates that the drug provides considerable hemodynamic benefit in cardiac dysfunction and is therefore a potentially salutary agent for treatment of patients with chronic severe congestive heart failure."
2.	Hypertension (High Blood Pressure) 01/01/1988 - "Effect on resting blood pressure and blood pressure homeostasis of short-term administration of the alpha 1-adrenergic receptor antagonist, trimazosin, in hypertension." 02/01/1987 - "A single-blind study was conducted to evaluate the blood pressure (BP) reduction and side effects of a sustained-release (SR) formulation of trimazosin in patients with mild to moderate hypertension. " 11/01/1983 - "Clinical hemodynamic profile of trimazosin in hypertension." 11/01/1983 - "Because of its excellent safety and toleration profile, trimazosin may be particularly suitable in first-line therapy of patients with mild or moderate hypertension." 01/01/1986 - "The kinetics and short-term (10 weeks) effects of trimazosin, an alpha 1-adrenoreceptor antagonist, on renal function and blood pressure in patients with moderate chronic renal insufficiency and hypertension, have been studied for the first time. "
3.	Renal Insufficiency (Renal Failure) 11/01/1983 - "Our conclusions are as follows: (1) trimazosin is an effective and safe antihypertensive agent given in single daily doses; (2) it exerts its effects mainly through direct arteriolar dilatation and less through autonomic inhibition; (3) its antihypertensive effectiveness is not compromised by the development of tolerance; (4) it exerts a selective beneficial effect on renal circulation that is unrelated to systemic hemodynamic changes; and (5) these properties of trimazosin may make it a desirable drug for the treatment of hypertension complicated by renal failure." 01/01/1986 - "Thus, trimazosin, as second-step antihypertensive agent, appeared to be safe and effective in patients with moderate renal insufficiency and hypertension, without exerting favourable or adverse renal effects during short-term therapy."
4.	Dyspnea (Shortness of Breath) 07/01/1978 - "Trimazosin and prazosin therapy was also effective in diminishing clinical symptoms, in lessening roentgenographic evidence of pulmonary venous congestion and in improving exercise duration until marked dyspnea. " 11/01/1977 - "The effect of the vasodilator trimazosin versus placebo on exercise duration until marked dyspnea was evaluated in a double blind randomized study in 16 patients with chronic left ventricular failure despite digitalis and diuretic therapy. "
5.	Hyperemia 11/01/1977 - "Four of eight patients receiving trimazosin had disappearance of pulmonary venous congestion on chest roentgenography compared with none of eight patients receiving placebo. " 07/01/1978 - "Trimazosin and prazosin therapy was also effective in diminishing clinical symptoms, in lessening roentgenographic evidence of pulmonary venous congestion and in improving exercise duration until marked dyspnea. "

Related Drugs and Biologics

1.	Antihypertensive Agents (Antihypertensives)
2.	Prazosin (Minipress)
3.	Vasodilator Agents (Vasodilators)
4.	Atenolol (Tenormin)
5.	Quinazolines
6.	carbazeran
7.	pirbuterol (Maxair)
8.	Methyldopa (Aldomet)
9.	Diuretics
10.	Adrenergic Receptors (Adrenergic Receptor)

Related Therapies and Procedures

1.	Therapeutics
2.	Intravenous Administration
3.	Oral Administration